{"id":"monoclonal-antibody-ch14-18","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ch14.18 works by binding to GD2, which helps the immune system recognize and attack cancer cells. This can lead to the destruction of cancer cells and the slowing of tumor growth.","oneSentence":"Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:03.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory neuroblastoma"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT01711554","phase":"PHASE1","title":"Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-04","conditions":"Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":27},{"nctId":"NCT07437963","phase":"PHASE1, PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":"Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT06995872","phase":"PHASE1","title":"Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-21","conditions":"Neuroblastoma","enrollment":34},{"nctId":"NCT04751383","phase":"PHASE1","title":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma","enrollment":12},{"nctId":"NCT07261241","phase":"PHASE2","title":"NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab","status":"NOT_YET_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2026-07-31","conditions":"Neuroblastoma","enrollment":118},{"nctId":"NCT04385277","phase":"PHASE2","title":"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-12-31","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":41},{"nctId":"NCT02914405","phase":"PHASE1","title":"Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2018-05-24","conditions":"Neuroblastoma","enrollment":44},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT03332667","phase":"PHASE1","title":"MIBG With Dinutuximab +/- Vorinostat","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2018-09-12","conditions":"Neuroblastoma","enrollment":45},{"nctId":"NCT02169609","phase":"PHASE2","title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2014-11-26","conditions":"Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy","enrollment":24},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT02258815","phase":"PHASE2","title":"CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2010-08","conditions":"Neuroblastoma Recurrent","enrollment":35},{"nctId":"NCT02484443","phase":"PHASE2","title":"Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-04","conditions":"Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma","enrollment":41},{"nctId":"NCT02641782","phase":"PHASE2","title":"NB2013-HR German (GPOH) / Dutch (DCOG) Trial","status":"TERMINATED","sponsor":"University of Cologne","startDate":"2015-11","conditions":"Neuroblastoma","enrollment":3},{"nctId":"NCT01767194","phase":"PHASE2","title":"Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-12","conditions":"Ganglioneuroblastoma, Recurrent Neuroblastoma","enrollment":73},{"nctId":"NCT02743429","phase":"PHASE2","title":"Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2015-03-27","conditions":"Neuroblastoma","enrollment":40},{"nctId":"NCT01041638","phase":"PHASE3","title":"Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-12-21","conditions":"High Risk Neuroblastoma","enrollment":105},{"nctId":"NCT03098030","phase":"PHASE2, PHASE3","title":"Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2017-06-01","conditions":"Small Cell Lung Cancer","enrollment":483},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT01704872","phase":"PHASE1","title":"ch14.18/CHO Bridging Study","status":"COMPLETED","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2005-07","conditions":"Neuroblastoma","enrollment":16},{"nctId":"NCT01701479","phase":"PHASE1, PHASE2","title":"Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2012-01","conditions":"Neuroblastoma","enrollment":288},{"nctId":"NCT01418495","phase":"","title":"Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome","enrollment":12},{"nctId":"NCT01592045","phase":"PHASE1, PHASE2","title":"ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2012-08","conditions":"Neuroblastoma","enrollment":28},{"nctId":"NCT00030719","phase":"PHASE3","title":"Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"University of Leicester","startDate":"2001-12","conditions":"Neuroblastoma","enrollment":175},{"nctId":"NCT00005576","phase":"PHASE1","title":"Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-01","conditions":"Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ch14.18","MOAB Ch14.18"],"phase":"phase_3","status":"active","brandName":"monoclonal antibody Ch14.18","genericName":"monoclonal antibody Ch14.18","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells. Used for Relapsed or refractory neuroblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}